P-152 YI No Iron and No Anemia: Who Are These Crohn's Patients and What Is Their Evolution?. (February 2017)

• Record Type: Journal Article
• Authors: Curdia Gonçalves, Tiago; Monteiro, Sara; Barbosa, Mara; Moreira, Maria João; Cotter, José
• Is Part Of: Inflammatory bowel diseases. Volume 23(2017)Supplement 1
• Publication Date: 2017-02
• Subjects: Inflammatory bowel diseases -- Periodicals; Colitis, Ulcerative -- Periodicals; Crohn Disease -- Periodicals; Inflammatory Bowel Diseases -- Periodicals; 616.344
• DOI: 10.1097/01.MIB.0000512670.24595.5c
• Languages: English
• ISSNs: 1078-0998

Abstract

Abstract : Background: Despite many studies exist about anemia in Crohn's Disease (CD), information about iron-deficiency without anemia (IDWA) is still scarce. The aim of this study was to characterize CD patients who had IDWA, as well as their evolution during the follow-up. Methods: CD patients who had at least one episode of IDWA between January of 2011 and December of 2014 were included in our study. Iron-deficiency was defined as serum ferritin <30 μg/L in the absence of inflammation or serum ferritin between 30 and 100 μg/L when inflammation was present. Besides characterization of patients' evolution during the follow-up, demographic and clinical differences between the 2 groups were also evaluated using the χ2 and the Fisher's Exact tests. Results: From the 136 patients with IDWA, 97 (71.3%) were women and the mean follow-up duration was 42 ± 16 months. Regarding the evolution, 43 patients (31.6%) developed anemia, 51 (37.5%) had recovery of the IDWA during the follow-up, 35 (25.7%) had persistent IDWA, and in 7 patients (5.2%) recurrence of IDWA was observed after an initial recovery. Only 8 patients (5.9%) received iron supplements for IDWA. There were no differences between the group with serum ferritin <30 μg/L and the group with serum ferritin between 30 and 100 μg/L concerning gender ( P = 0.849), extension ( P = 0.91) or behavior of disease ( P = 0.056), age at the diagnosis ( P = 0.401), perianal ( P = 0.571) or upper gastrointestinal tract involvement ( P = 0.749), family history of inflammatory bowel disease ( P = 0.051) or smoking habits ( P = 0.555). Despite the development of anemia did not differ significantly between the 2 groups ( P = 0.957), recovery was significantly higher in patients with ferritin between 30 and 100 μg/L ( P = 0.025). Conclusions: Although IDWA is transient in about one third of patients with CD, another third of the patients will develop anemia during the follow-up. This result highlights the importance of investigation and follow-up of IDWA, particularly in patients with lower values of serum ferritin, in whom recovery is not so frequent.